Lilly launches TruAssist
INDIANAPOLIS — Drug maker Eli Lilly has launched what it’s calling an “umbrella” for its patient assistance programs.
Lilly subsidiary Lilly USA announced the launch of TruAssist, which comprises a website and call center for patients and healthcare providers to access information about programs the company provides to help increase access to Lilly medications. The website is at LillyTrueAssist.com, while the call center can be reached at 1-855-LLYTRUE (1-855-559-8783).
“In 2010, Lilly helped approximately 227,000 people in the United States obtain the Lilly medications they need,” Lilly U.S. medical division VP Jack Harris said. “With TruAssist, our goal is to further our commitment to improving patients’ lives by increasing awareness of these programs and giving healthcare providers and patients one easy-to-use resource for accessing them.”
APhA encourages seniors to talk to pharmacists
WASHINGTON — The American Pharmacists Association is marking Older Americans Month by urging seniors to increase their knowledge about medications and wellness by talking to their pharmacists, the group said Monday.
The APhA said that as the most accessible healthcare providers and medication experts, pharmacists are ready to discuss issues that arise due to medications and age. This include helping seniors understand their medications and how to take them properly, the differences between branded and generic drugs, over-the-counter medications and herbal supplements and what kinds of side effects they might have, reading labels and dosing information and other topics.
The group also encourages consumers to fill their prescriptions at one pharmacy and get to know their pharmacist on a first-name basis.
Mylan’s generic Xibrom ophthalmic solution enters market
PITTSBURGH — Mylan has launched a generic drug for treating post-operative inflammation in patients who have undergone cataract extraction, the company said Monday.
Mylan announced the launch of bromfenac ophthalmic solution in the 0.09% strength, for twice-daily administration, under a development and supply agreement with Coastal Pharmaceuticals.
The drug is a generic version of ISTA’s Xibrom ophthalmic solution. Various versions of bromfenac ophthalmic solution had sales of about $116 million during the 12-month period ended in March, according to IMS Health.